NICE U-turn sees Revestive now backed for the treatment of SBS

The UK subsidiary of Japan’s Takeda (TYO: 4502) today announced that the National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Document (FAD) recommending Revestive (teduglutide) once daily subcutaneous injection as an option for people living with short bowel syndrome (SBS) aged one year and above. Individuals should be stable following a period of intestinal adaptation after surgery.

Developed by Shire that is now a part of Takeda, Revestive was rejected by the health technology appraisal body in England and Wales for SBS in 2017.

SBS is a rare, serious and disabling gastrointestinal condition, that results from the loss of some or all of the small intestine due to congenital abnormalities, disease or trauma. As a result of this, people living with SBS lose the ability to absorb enough nutrients and liquid through a normal diet and need to receive life-sustaining nutrition intravenously, known as parenteral nutrition (PN) or parenteral support (PS) – a complex, sophisticated treatment that involves intravenous delivery of nutrition and fluids through a catheter averaging 10-14 hours overnight for two–seven nights a week.